Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.52 |
| ▸ | RXRB | P28702 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 7/20 | 0.48 |
| ▸ | CLK1 | P49759 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14492793 | 1.00 | RXRA (0.52) | RXRARXRBGSK3BCLK1DYRK1A | |
| SCHEMBL14492789 | 0.88 | RXRA (0.50) | RXRARXRBCLK1DYRK1AMAPT | |
| SCHEMBL1619225 | 0.82 | RXRA (0.53) | RXRARXRBGSK3BRAB9AHPGD | |
| SCHEMBL14492781 | 0.82 | RXRA (0.53) | RXRARXRBGSK3BRAB9AHPGD | |
| SCHEMBL14492783 | 0.78 | CSNK2A2 (0.53) | RXRARXRBCLK1DYRK1ARAB9A | |
| SCHEMBL15302978 | 0.74 | GSK3B (0.62) | GSK3BCLK1DYRK1AMAPTLMNA | |
| SCHEMBL15302979 | 0.74 | GSK3B (0.62) | GSK3BCLK1DYRK1AMAPTLMNA | |
| SCHEMBL1619286 | 0.74 | POLB (0.52) | RXRARXRBGSK3BCLK1DYRK1A | |
| SCHEMBL5483942 | 0.72 | RARG (0.52) | GSK3BCLK1DYRK1AMAPTLMNA | |
| SCHEMBL5483946 | 0.72 | RARG (0.52) | GSK3BCLK1DYRK1AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392326-B1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | ORTHO MCNEIL JANSSEN PHARM (US) | 2009-09-09 | — | — | EP | claimed |
| US-20090075864-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | BUSSOLARI JACQUELINE C | 2009-03-19 | — | — | US | claimed |
| US-6838442-B2 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-01-04 | — | — | US | claimed |
| EP-1392326-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | Ortho McNeil Pharmaceutical, Inc. (US) | 2004-03-03 | — | — | EP | claimed |
| US-20030195235-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators | BUSSOLARI JACQUELINE C (US) | 2003-10-16 | — | — | US | claimed |
| US-20030055091-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-03-20 | — | — | US | claimed |
| WO-2002080935-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-10-17 | — | — | WO | claimed |
| EP-1214304-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | claimed |
| WO-2001016122-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| US-8796313-B2 | Substituted dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-08-05 | — | — | US | disclosed |
| US-8680122-B2 | Substituted pyrrolones as allosteric modulators of glucokinase | JANSSEN PHARMACETICA N.V. (BE) | 2014-03-25 | — | — | US | disclosed |
| US-8236819-B2 | Dihydro-[1H]-quinolin-2-one derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-07 | — | — | US | disclosed |
| US-8183213-B2 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-7928246-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| US-20030153606-A1 | Thiazolidinedione derivatives for the treatment of diabetes and other diseases | MAXIA PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| US-20030055091-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-03-20 | — | — | US | disclosed |
| US-6515003-B1 | Useful in the treatment of diseases related to lipid and carbohydrate metabolism | MAXIA PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
| WO-2002080935-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| EP-1214304-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001016122-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055091-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators | GPR119, SLC2A4, SLC2A1 | RXRA 11/4885RXRB 9/4885GSK3B 3736/4885 |
| US-20030195235-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators | GPR119, SLC2A4, SLC2A1 | RXRA 11/4885RXRB 9/4885GSK3B 3736/4885 |
| US-20030153606-A1 | Thiazolidinedione derivatives for the treatment of diabetes and other diseases | FABP4, PPARG, CPT2 | RXRA 247/4885RXRB 232/4885GSK3B 774/4885 |
| US-20090075864-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | GPR119, SLC2A4, SLC2A1 | RXRA 11/4885RXRB 9/4885GSK3B 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.